Literature DB >> 35706848

Research on Portal Venous Hemodynamics and Influencing Factors of Portal Vein System Thrombosis for Wilson's Disease after Splenectomy.

Zhou Zheng1,2, Qingsheng Yu1,2, Hui Peng1,2, Wanzong Zhang1,2, Yi Shen1,2, Hui Feng1,2, Long Huang1,2, Fuhai Zhou1,2, Qi Zhang1,2, Qin Wang1.   

Abstract

Objective: Splenectomy is one crucial solution for hypersplenism with portal hypertension. However, portal vein system thrombosis (PVST) caused by hemodynamic changes affects the prognosis of patients. We analyze the changes in portal vein hemodynamics following splenectomy for Wilson's disease combined with portal hypertension and the influencing factors that lead to PVST.
Methods: A retrospective cohort study was conducted, in which 237 Wilson's disease patients with hypersplenism underwent splenectomy. The hemodynamic indices of the portal vein were monitored before surgery and on the 1st, 7th, and 14th days around surgery. The patients were divided into PVST and non-PVST groups. The clinical factors were identified by univariate and multivariate logistic regression. The Logit P was calculated according to the logistic regression prediction model, and the ROC curve for each independent factor was plotted.
Results: The portal vein velocity, flow, and inner diameter showed a downward trend around surgery, with statistically significant differences between each time point (P < 0.01). The PVST incidence rate was 55.7%. Univariate analysis revealed that the platelet (PLT) levels on the postoperative 3rd and 7th days (P = 0.001; P < 0.001), D-dimer (D-D) on the postoperative 7th and 14th days (P = 0.002; P < 0.001), preoperative portal vein velocity, flow, diameter (P < 0.001), and splenic vein diameter (P < 0.001) were all statistically and significantly different between the two groups. Multivariate logistic regression revealed a significant increase in PLT on the postoperative 7th day (OR = 1.043, 95% CI, 1.027-1.060, P < 0.001) and D-D on the postoperative 14th day (OR = 1.846, 95% CI, 1.400-2.435, P < 0.001). Preoperative portal and splenic vein diameters (OR = 1.565, 95% CI, 1.213-2.019, P = 0.001; OR = 1.671, 95% CI, 1.305-2.140, P < 0.001) were the risk factors for PVST. However, preoperative portal vein velocity and flow (OR = 0.578, 95% CI, 0.409-0.818, P = 0.002; OR = 0.987, 95% CI, 0.975-0.990, P = 0.046) were protective factors for PVST. Logit P was calculated using a logistic regression prediction model with a cut-off value of -0.32 and an area under receiver operating characteristic curve of 0.952 with 88.61% accuracy. Conclusions: Splenectomy relieves portal hypertension by reducing the hemodynamics index. PVST is linked to multiple factors, including preoperative portal vein diameter, velocity, flow, and splenic vein diameter, especially PLT on the postoperative 7th day and D-D on the postoperative 14th day. The predictive model is accurate in predicting PVST.
Copyright © 2022 Zheng, Yu, Peng, Zhang, Shen, Feng, Huang, Zhou, Zhang and Wang.

Entities:  

Keywords:  Wilson’s disease; hemodynamic; hypertension; portal vein system thrombosis (PVST); splenectomy

Year:  2022        PMID: 35706848      PMCID: PMC9189385          DOI: 10.3389/fsurg.2022.834466

Source DB:  PubMed          Journal:  Front Surg        ISSN: 2296-875X


  40 in total

1.  Effective Prevention for Portal Venous System Thrombosis After Splenectomy: A Meta-Analysis.

Authors:  Xiao Zhang; Yadong Wang; Miao Yu; Jinzhao Huang; Dongfeng Deng; Huanzhou Xue
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2017-02-16       Impact factor: 1.878

2.  The incidence and risk factors of portal vein system thrombosis after splenectomy and pericardial devascularization.

Authors:  Shengli Wu; Zheng Wu; Xiaogang Zhang; Ruitao Wang; Jigang Bai
Journal:  Turk J Gastroenterol       Date:  2015-09       Impact factor: 1.852

3.  Combined Rex-bypass shunt with pericardial devascularization alleviated prehepatic portal hypertension caused by cavernomatous transformation of portal vein.

Authors:  Ruo-Yi Wang; Jun-Feng Wang; Qian Liu; Nan Ma; Wei-Xiu Chen; Jin-Liang Li
Journal:  Postgrad Med       Date:  2017-06-23       Impact factor: 3.840

4.  De-novo portal vein thrombosis in liver cirrhosis: risk factors and correlation with the Model for End-stage Liver Disease scoring system.

Authors:  Ahmed Abdel-Razik; Nasser Mousa; Rania Elhelaly; Ahmed Tawfik
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-05       Impact factor: 2.566

5.  Significance of Amylase Monitoring in Peritoneal Drainage Fluid after Splenectomy: A Clinical Analysis of Splenectomy in 167 Patients with Hepatolenticular Degeneration.

Authors:  Yi Shen; Binbin Guo; Laiyong Wang; Hui Peng; Jinfang Pan; Qi Zhang; Long Huang; Fuhai Zhou; Qingsheng Yu
Journal:  Am Surg       Date:  2020-04-01       Impact factor: 0.688

6.  Laparoscopic splenectomy plus preoperative endoscopic variceal ligation versus splenectomy with pericardial devascularization (Hassab's operation) for control of severe varices due to portal hypertension.

Authors:  Jin Zhou; Zhong Wu; Junchao Wu; Bing Peng; Xin Wang; Mingjun Wang
Journal:  Surg Endosc       Date:  2013-07-12       Impact factor: 4.584

7.  Short-term effects of splenectomy on serum fibrosis indexes in liver cirrhosis patients.

Authors:  Degang Kong; Xiuli Chen; Shichun Lu; Qingliang Guo; Wei Lai; Jushan Wu; Dongdong Lin; Daobing Zeng; Binwei Duan; Tao Jiang; Jilei Cao
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

8.  Management Perspective of Wilson's Disease: Early Diagnosis and Individualized Therapy.

Authors:  Xiang-Zhen Yuan; Ren-Min Yang; Xiao-Ping Wang
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

9.  Role of D-dimer in the Development of Portal Vein Thrombosis in Liver Cirrhosis: A Meta-analysis.

Authors:  Junna Dai; Xingshun Qi; Hongyu Li; Xiaozhong Guo
Journal:  Saudi J Gastroenterol       Date:  2015 May-Jun       Impact factor: 2.485

Review 10.  Inflammation and haemostasis.

Authors:  Sandra Margetic
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.